Voxilaprevir: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) Stub |
No edit summary |
||
Line 54: | Line 54: | ||
==References== |
==References== |
||
{{ |
{{Reflist}} |
||
{{RNA antivirals}} |
|||
[[Category:NS3/4A protease inhibitors]] |
[[Category:NS3/4A protease inhibitors]] |
Revision as of 05:46, 28 June 2017
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and has received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[1]
References
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.